Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Status:
Terminated
Trial end date:
2006-08-11
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine and arsenic trioxide, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer
cells.
PURPOSE: This phase II trial is studying how well giving azacitidine together with arsenic
trioxide works in treating patients with myelodysplastic syndromes or chronic myelomonocytic
leukemia.